|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Metastatic pancreatic cancer: Is there a light at the end of the tunnel?显示文摘Due to extremely poor prognosis,pancreatic cancer(PDAC)represents the fourth leading cause of cancerrelated death in Western countries.For more than a decade,gemcitabine(Gem)has been the mainstay of first-line PDAC treatment.Many efforts aimed at improving single-agent Gem efficacy by either combining it with a second cytotoxic/molecularly targeted agent or pharmacokinetic modulation provided disappointing results.Recently,the field of systemic therapy of advanced PDAC is finally moving forward.Polychemotherapy has shown promise over single-agent Gem:regimens like PEFG-PEXG-PDXG and GTX provide significant potential advantages in terms of survival and/or disease control,although sometimes at the cost of poor tolerability.The PRODIGE 4/ACCORD 11 was the first phaseⅢtrial to provide unequivocal benefit using the polychemotherapy regimen FOLFIRINOX;however the less favorable safety profile and the characteristics of the enrolled population,restrict the use of FOLFIRINOX to young and fit PDAC patients.The nanoparticle albumin-bound paclitaxel(nab-Paclitaxel)formulation was developed to overcome resistance due to the desmoplastic stroma surrounding pancreatic cancer cells.Regardless of whether or not this is its main mechanisms of action,the combination of nabPaclitaxel plus Gem showed a statistically and clinically significant survival advantage over single agent Gem and significantly improved all the secondary endpoints.Furthermore,recent findings on maintenance therapy are opening up potential new avenues in the treatment of advanced PDAC,particularly in a new era in which highly effective first-line regimens allow patients to experience prolonged disease control.Here,we provide an overview of recent advances in the systemic treatment of advanced PDAC,mostly focusing on recent findings that have set new standards in metastatic disease.Potential avenues for further development in the metastatic setting and current efforts to integratenew effective chemotherapy regimens in earlier stages of disease(neoadjuvant,adjuvant,and multimodal approaches in both resectable and unresectable patients)are also briefly discussed. | Vanja Vaccaro Isabella Sperduti Sabrina Vari Emilio Bria Davide Melisi Carlo Garufi Carmen Nuzzo Aldo Scarpa Giampaolo Tortora Francesco Cognetti Michele Reni Michele Milella | 2015 | World Journal of Gastroenterology2015，21，16： | 2 |
| 2 | Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group显示文摘 | Marry M Cognetti F Maraninchi D | 2005 | J Clin Oncol2005，23，19： | 1 |
| 3 | Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor 2-positive metastatic breast cancer administered as first-line treatment:the M77001 study group显示文摘 | Marty M Cognetti F Maraninchi D | 2005 | J Clin Oncol2005，23，19： | 1 |
| 4 | New drugs in the treatment of recurrent or metastatic cervical cancer 显示文摘 | Antonella Savarese Francesco Cognetti | 2003 | Critical Reviews on Oncology Pdematology2003，48，30： | 1 |
| 5 | Early adoption of transoral robotic surgical program: preliminary outcomes 显示文摘 | Cognetti DM Luginbuhl AJ Nguyen AL | 2012 | Otolaryngol Head Neck Surg2012，147，3： | 1 |
| 6 | Effect of low environmental temperature on embryonic development and egg hatching of Diplectanum aequans ( Monogenea, Dipleetanidae) infecting Europe- an sea bass,Dicentrarchus labrax 显示文摘 | Cecchini S Saroglia M Cognetti - Varriale AM Terova G Sabino G | 2001 | Fish Pathology2001，36，1： | 1 |
| 7 | Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with do- cetaxel in patients with human epidermal growth factor receptor 2- positive metastatic breast cancer administered as first-line treat- ment: The M77001 study group 显示文摘 | Marry M Cognetti F Maraninchi D | 2005 | J Clin Oncol2005，23，19： | 1 |
| 8 | Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group显示文摘 | Marry M Cognetti F Maraninehi D | 2005 | J Clin Oncol2005，23，19： | 1 |
| 9 | Trastuzumab (lderceptin) plus docetaxel versus docetaxel alone as first line treatment of HER2-positive me- tastatic breast cancer (MBC) : results of a randomised muhicentre trial显示文摘 | SExtra JM Cognetti F Maraninchi D et at | 2004 | Eur J Cancer2004，，12： | 1 |
| 10 | Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group 显示文摘 | Marty M Cognetti F Maraninchi D | 2005 | J Clin Oncol2005，3，： | 1 |
| 11 | Randomized phase Htrial of the efficacy and safety of trastuzumab combined withdocetaxel in patients with human epidermal growth factor receptor2-positive metastatic breast cancer administered as first-linetreatment : the M77001 study group 显示文摘 | Marty M Cognetti F Maraninchi D | 2005 | J Clin Oncol2005，23，42： | 1 |
| 12 | 672 Randomised phase Ⅱ trial (M77001) of trastuzumab (Herceptin(R显示文摘 | Extra J M Cognetti F Chan S | | 0，，05： | 1 |
| 13 | Future directions in the second - line treatment of non - small cell lung cancer显示文摘 | Rosell R Cecere F Cognetti F | 2006 | Semin Oncol2006，33，11： | 1 |
| 14 | Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2 - positive metastatic breast cancer administered, as first-line treatment: The M77001 study group 显示文摘 | Marty M Cognetti F Maraninchi D | 2005 | J Clin Oncol2005，23，19： | 1 |
| 15 | Quality of life, functional outcome and costs of early glottic cancer 显示文摘 | Smith JC Johnson JT Cognetti DM | 2003 | Laryngoscope2003，113，： | 1 |
| 16 | Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:the M77001 study group显示文摘 | Marty M Cognetti F Maraninchi D | 2005 | J Clin Oncol2005，23，19： | 1 |
| 17 | New drugs in the treatment of recurrent or metastatic cervical cancer显示文摘 | Savarese A Cognetti F | 2003 | Crit Rev Oncol Hematol2003，48，3： | 1 |
| 18 | Trastuzumab (Herceptin) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC):results of a randomised multicentre trial显示文摘 | EXTRA J M COGNETTI F MARANICHI D | 2004 | Eur J Cancer Suppl2004，2，3： | 1 |
| 19 | New drugs in the treatment of recurrent or metastatic cervical cancer显示文摘 | SAVARESE A COGNETTI F | 2003 | Crit Rev Oncol Hematol2003，45，3： | 1 |
| 20 | Endomeiosis and sex determination in Daphnia pulex 显示文摘 | Bacci G Cognetti G Vaccari A | 1961 | Experientia1961，17，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员